Enjoy complimentary customisation on priority with our Enterprise License!
The global conjugate vaccines market size has the potential to grow by USD 7.27 billion during 2020-2024. The market’s growth momentum will accelerate throughout the forecast period because of the steady increase in year-over-year growth.
This report provides a detailed analysis of the market by type (multivalent conjugate vaccine and monovalent conjugate vaccine) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.
Browse TOC and LoE with selected illustrations and example pages of conjugate vaccines market
The conjugate vaccines market is currently moderately fragmented. The degree of fragmentation will increase slightly over the forecast period. With significant business growth scope in the market, vendors are focusing on R&D to release novel conjugate vaccines, which will increase their market penetration and revenue generation. Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. are a few of the significant market participants. Although the awareness about immunization programs, and access to vaccines will offer immense business opportunities to vendors, the high cost associated with vaccine research, development, and manufacturing will challenge the growth of many. To make the most of the possibilities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market positions, this conjugate vaccines market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of the companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. This conjugate vaccines market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of their future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading conjugate vaccines companies, including:
For more insights on the conjugate vaccines market share of various regions Request for a FREE sample now!
North America accounted for the largest market share in 2019, and the region will continue to offer maximum growth opportunities to vendors over the forecast period. The prevalence of infectious diseases such as pneumococcal diseases, influenza, diphtheria, tetanus, pertussis, and meningococcal is fueling the demand for conjugate vaccines in North America. Moreover, the regional market is recording an increasing number of initiatives to raise awareness about immunization programs and improve access to vaccines.
Almost 48% of the overall market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for conjugate vaccines in the region. The market growth rate in this region will be slower than that of Asia over the forecast period.
Request for a FREE sample and Get more information on the market contribution from various types of conjugate vaccines
Multivalent conjugate vaccines are widely used to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases. The US FDA has approved many multivalent conjugate vaccines, which is expected to increase sales. As a result, the conjugate vaccines market growth by the multivalent conjugate vaccines segment will be significant over the forecast period.
The growth rate of the multivalent conjugate vaccine segment is expected to be slower compared with the monovalent conjugate vaccine segment over the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the conjugate vaccines market size.
Typhoid, pneumonia, meningitis, tetanus, diphtheria, and pertussis can cause serious harm, especially to infants and children. The lack of awareness about immunization can lead to the continuation of these deadly diseases. Therefore, increasing awareness about immunization programs and access to vaccines have become essential. Organizations across the world are taking many initiatives to raise awareness about immunization programs. Immunization programs are well-recognized and successful public health programs worldwide. Also, there are initiatives aimed at increasing access to vaccines worldwide. For instance, the International Medical Humanitarian Organization rolled out a vaccination campaign named Humanitarian Mechanism in May 2017 to provide access to expensive pneumonia vaccines to refugee children on the Greek islands of Chios, Samos, and Lesvos. These factors are expected to increase sales of conjugate vaccines over the forecast period, contributing to the global conjugate vaccines market growth.
We can help! Our analysts can customize this report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.